Stocks and Investing Stocks and Investing
Thu, November 3, 2022

Gregory Renza Maintained (ACAD) at Buy with Decreased Target to $21 on, Nov 3rd, 2022


Published on 2024-10-27 23:52:17 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $22 to $21 on, Nov 3rd, 2022.

Gregory has made no other calls on ACAD in the last 4 months.



There are 8 other peers that have a rating on ACAD. Out of the 8 peers that are also analyzing ACAD, 5 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $15 on, Wednesday, August 10th, 2022
  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $19 on, Wednesday, August 10th, 2022
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $18 on, Tuesday, August 9th, 2022
  • Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $15 on, Monday, August 8th, 2022


These are the ratings of the 3 analyists that currently disagree with Gregory


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $25 on, Tuesday, August 9th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $21 on, Tuesday, August 9th, 2022
  • Ritu Baral of "Cowen & Co." Maintained at Buy with Decreased Target to $21 on, Monday, August 8th, 2022
Contributing Sources